AstraZeneca was among the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative’s corporate net zero standard. Investment in green gas, reforestation and the associated use of AI mark the company out as a thought leader in sustainability initiatives. In this context, COP28’s renewed focus on ‘climate+health’ is well timed.
The adoption of corporate climate change efforts and initiatives continues to expand, including by health care companies, although they are frequently cast as being slow out of the blocks to modernize and embrace change.
Not so the health care players with whom In Vivo has spoken over the past 18 months for its rolling...
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
